Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HIK.LSE
- Price
- 1830.00
- Stock movement down
- -9.00 (-0.49%)
- Company name
- Hikma Pharmaceuticals PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 406.05B
- Ent value
- 408.36B
- Price/Sales
- 91.37
- Price/Book
- 176.54
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- 44.27%
- Trailing P/E
- 976.08
- Forward P/E
- 788.35
- PEG
- -
- EPS growth
- -15.64%
- 1 year return
- 2.46%
- 3 year return
- -3.96%
- 5 year return
- -3.88%
- 10 year return
- -1.46%
Last updated: 2025-04-12
DIVIDENDS
HIK.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 976.08 |
| Price to OCF | 442.80 |
| Price to FCF | 637.44 |
| Price to EBITDA | 263.93 |
| EV to EBITDA | 265.43 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 91.37 |
| Price to Book | 176.54 |
| EV to Sales | 91.89 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 221.88M |
| EPS (TTM) | 1.86 |
| FCF per share (TTM) | 2.85 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.44B |
| Gross profit (TTM) | 2.16B |
| Operating income (TTM) | 970.00M |
| Net income (TTM) | 416.00M |
| EPS (TTM) | 1.86 |
| EPS (1y forward) | 2.32 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 48.67% |
| Operating margin (TTM) | 21.83% |
| Profit margin (TTM) | 9.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 236.00M |
| Net receivables | 937.00M |
| Total current assets | 2.29B |
| Goodwill | 383.00M |
| Intangible assets | 711.00M |
| Property, plant and equipment | 0.00 |
| Total assets | 4.85B |
| Accounts payable | 541.00M |
| Short/Current long term debt | 1.28B |
| Total current liabilities | 1.38B |
| Total liabilities | 2.55B |
| Shareholder's equity | 2.30B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 917.00M |
| Capital expenditures (TTM) | 280.00M |
| Free cash flow (TTM) | 637.00M |
| Dividends paid (TTM) | 282.00M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 18.09% |
| Return on Assets | 8.58% |
| Return on Invested Capital | 16.54% |
| Cash Return on Invested Capital | 25.33% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1859.00 |
| Daily high | 1859.00 |
| Daily low | 1813.00 |
| Daily Volume | 407K |
| All-time high | 2695.00 |
| 1y analyst estimate | 2361.45 |
| Beta | 0.43 |
| EPS (TTM) | 1.86 |
| Dividend per share | - |
| Ex-div date | 20 Mar 2025 |
| Next earnings date | 25 Apr 2025 |
Downside potential
Loading...
Downside potential data
| HIK.LSE | S&P500 | |
| Current price drop from All-time high | -32.10% | -12.89% |
| Highest price drop | -68.03% | -56.47% |
| Date of highest drop | 13 Feb 2018 | 9 Mar 2009 |
| Avg drop from high | -20.35% | -11.07% |
| Avg time to new high | 27 days | 12 days |
| Max time to new high | 1138 days | 1805 days |
COMPANY DETAILS
Marketcap
406.05B
Marketcap category
Large-cap
Description
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Employees
9100
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found